Abemaciclib Poised to Be New Standard of Care in Aggressive Liposarcoma

(MedPage Today) -- CHICAGO -- Treatment with the CDK4/6 inhibitor abemaciclib (Verzenio) offered a dramatic survival uptick in a highly aggressive soft-tissue cancer that rarely responds to chemotherapy, according to the SARC041 trial. Patients...
Source
MedPage Today
Opens original article in a new tab



